Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BrainsWay Ltd.'s quarterly P/E stands at 17.0x, down 40.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 39.4% YoY to 15.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 45.61 | 16.98 | 47.13 | 32.90 | 59.25 | 28.64 | 28.88 | 38.00 | 200.76 | 207.69 | — | — | — |
| — | -40.7% | +63.2% | -13.4% | -70.5% | -86.2% | — | — | — | — | — | — | — | |
| P/S Ratio | 6.12 | 3.40 | 5.30 | 4.92 | 3.79 | 3.89 | 3.67 | 2.53 | 2.42 | 2.98 | 2.02 | 1.21 | 1.10 |
| — | -12.5% | +44.5% | +94.4% | +56.4% | +30.4% | +81.7% | +109.7% | +121.0% | +75.6% | -30.1% | -51.5% | -75.7% | |
| P/B Ratio | 4.76 | 2.72 | 4.09 | 3.65 | 2.74 | 2.85 | 3.50 | 2.36 | 2.10 | 2.59 | 1.63 | 0.91 | 0.68 |
| — | -4.5% | +16.8% | +54.8% | +30.7% | +10.0% | +115.2% | +157.8% | +210.1% | +186.9% | +33.1% | -38.5% | -73.8% | |
| P/FCF | 19.63 | 96.06 | 122.26 | 5.54 | 11.02 | 17.27 | 39.40 | 50.56 | 8.98 | 13.25 | 19.91 | — | — |
| — | +456.2% | +210.3% | -89.0% | +22.7% | +30.3% | +97.9% | — | — | — | — | — | — | |
| EV / EBITDA | 44.16 | 15.14 | 33.63 | 48.36 | 28.06 | 24.99 | 36.35 | 16.28 | 46.22 | 2.34 | 29.10 | — | — |
| — | -39.4% | -7.5% | +197.1% | -39.3% | +968.9% | +24.9% | — | — | — | — | — | — | |
| EV / EBIT | 59.87 | 17.92 | 30.82 | 16.22 | 14.71 | 41.80 | 23.85 | 13.03 | 26.65 | 19.61 | — | — | — |
| — | -57.1% | +29.2% | +24.4% | -44.8% | +113.2% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BrainsWay Ltd.'s operating margin was 13.2% in Q4 2025, up 3.9 pp QoQ and up 9.4 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 8.0% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.4% | 76.4% | 75.2% | 75.2% | 74.6% | 74.6% | 73.5% | 75.3% | 74.9% | 74.6% | 74.3% | 73.2% | 73.0% |
| — | +2.5% | +2.3% | -0.2% | -0.4% | -0.1% | -1.1% | +2.9% | +2.7% | +4.6% | +0.4% | +0.9% | -4.7% | |
| Operating Margin | 8.3% | 13.2% | 9.3% | 4.6% | 5.0% | 3.8% | 2.7% | 5.9% | 1.0% | 111.9% | -1.6% | -17.2% | -55.4% |
| — | +248.8% | +246.6% | -21.9% | +388.3% | -96.6% | +267.0% | +134.1% | +101.8% | +256.1% | +98.3% | +31.6% | -197.7% | |
| Net Margin | 14.6% | 20.2% | 11.6% | 16.0% | 9.6% | 13.6% | 6.3% | 6.0% | 1.2% | 1.4% | -2.8% | -21.2% | -36.7% |
| — | +48.7% | +83.9% | +167.6% | +686.2% | +864.2% | +327.5% | +128.2% | +103.3% | +102.2% | +97.2% | +30.6% | -46.7% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.4% | 4.1% | 2.3% | 3.1% | 1.8% | 2.9% | 1.5% | 1.4% | 0.3% | 0.3% | -0.6% | -3.9% | -5.5% |
| — | +41.5% | +48.9% | +117.7% | +561.3% | +849.0% | +373.1% | +135.8% | +104.8% | +103.7% | +94.3% | +11.9% | -56.1% | |
| ROA | 7.4% | 2.6% | 1.4% | 1.9% | 1.1% | 1.9% | 1.0% | 0.9% | 0.2% | 0.2% | -0.4% | -2.7% | -3.8% |
| — | +40.4% | +45.0% | +108.6% | +556.8% | +799.2% | +348.7% | +133.4% | +104.5% | +103.5% | +94.7% | +18.8% | -43.7% | |
| ROIC | 61.2% | 15.7% | 14.8% | 21.3% | — | — | — | 3.0% | 0.2% | 52.5% | — | — | — |
| — | — | — | +599.6% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BrainsWay Ltd.'s Debt/EBITDA ratio is 3.0x, down from 4.1x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 26.2% YoY to 3.83x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.10 | 0.09 | 0.09 | 0.09 | — | 0.10 | — | 0.01 | — | — | — |
| — | +3.2% | — | -11.5% | — | +696.8% | — | — | — | +5.4% | — | — | — | |
| Debt / EBITDA | 1.15 | 2.99 | 4.07 | 6.35 | 5.74 | 4.94 | — | 4.94 | — | 0.05 | — | — | — |
| — | -39.5% | — | +28.5% | — | +10845.6% | — | — | — | — | — | — | — | |
| Current Ratio | 3.83 | 3.83 | 3.19 | 3.51 | 5.03 | 5.19 | 4.52 | 4.70 | 4.48 | 5.68 | 6.36 | 6.98 | 6.13 |
| — | -26.2% | -29.4% | -25.4% | +12.3% | -8.6% | -28.9% | -32.7% | -26.9% | -20.4% | -7.1% | -9.4% | -22.3% | |
| Quick Ratio | 3.51 | 3.51 | 3.02 | 3.34 | 4.75 | 4.90 | 4.23 | 4.39 | 4.18 | 5.30 | 5.94 | 6.54 | 5.61 |
| — | -28.4% | -28.6% | -23.9% | +13.7% | -7.5% | -28.8% | -32.8% | -25.5% | -20.4% | -8.4% | -12.0% | -27.2% | |
| Interest Coverage | 1.96 | 4.45 | — | 0.74 | 0.98 | 2.48 | 0.75 | 1.46 | 0.22 | 63.14 | -0.62 | -2.32 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying BWAY stock.
BrainsWay Ltd.'s current P/E is 45.6x. The average P/E over the last 4 quarters is 39.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BrainsWay Ltd.'s current operating margin is 8.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BrainsWay Ltd.'s business trajectory between earnings reports.